Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Versameb has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in June 2023.
Versameb's investors include Bernina BioInvest.
Versameb is headquartered in Basel, Switzerland.
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Versameb is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Versameb — Funding & Investors." VCBacked, June 14, 2023, https://www.vcbacked.co/company/versameb. Accessed November 13, 2026.
VCBacked. (2023). Versameb — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/versameb
{{cite web |title=Versameb — Funding & Investors |url=https://www.vcbacked.co/company/versameb |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Versameb? Request a listing update